Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Bone Joint J. 2019 Jun;101-B(6_Supple_B):9-15. doi: 10.1302/0301-620X.101B6.BJJ-2018-1407.R1.
The aims of this study were to characterize antibiotic choices for perioperative total knee arthroplasty (TKA) and total hip arthroplasty (THA) prophylaxis, assess antibiotic allergy testing efficacy, and determine rates of prosthetic joint infection (PJI) based on perioperative antibiotic regimen.
We evaluated all patients undergoing primary TKA or THA at a single academic institution between January 2004 and May 2017, yielding 29 695 arthroplasties (22 705 patients), with 3411 arthroplasties in 2576 patients (11.5%) having undergone preoperative allergy testing. A series of institutional databases were combined to identify allergy consultation outcomes, perioperative antibiotic regimen, and infection-free survivorship until final follow-up.
Among 2576 allergy-tested patients, 2493 patients (97%) were cleared to use cephalosporins. For the entire cohort, 28 174 arthroplasties (94.9%) received cefazolin and 1521 (5.1%) received non-cefazolin antibiotics. Infection-free survivorship was significantly higher among arthroplasties receiving cefazolin compared with non-cefazolin antibiotics, with 0.06% higher survival free of infection at one month, 0.56% at two months, 0.61% at one year, and 1.19% at ten years (p < 0.001). Overall, the risk of PJI was 32% lower in patients treated with cefazolin after adjusting for the American Society of Anesthesiologists (ASA) classification, joint arthroplasty (TKA or THA), and body mass index (BMI; p < 0.001). The number needed to treat with cefazolin to prevent one PJI was 164 patients at one year and 84 patients at ten years. Therefore, potentially 6098 PJIs could be prevented by one year and 11 905 by ten years in a cohort of 1 000 000 primary TKA and THA patients.
PJI rates are significantly higher when non-cefazolin antibiotics are used for perioperative TKA and THA prophylaxis, highlighting the positive impact of preoperative antibiotic allergy testing to increase cefazolin usage. Given the low rate of true penicillin allergy positivity, and the readily modifiable risk factor that antibiotic choice provides, we recommend perioperative testing and clearance for all patients presenting with penicillin and cephalosporin allergies. Cite this article: 2019;101-B(6 Supple B):9-15.
本研究旨在描述围手术期全膝关节置换术(TKA)和全髋关节置换术(THA)预防中抗生素的选择,评估抗生素过敏检测的效果,并根据围手术期抗生素方案确定假体关节感染(PJI)的发生率。
我们评估了 2004 年 1 月至 2017 年 5 月期间在一家学术机构接受初次 TKA 或 THA 的所有患者,共 29695 例关节置换术(22705 例患者),其中 2576 例患者(11.5%)的 3411 例关节置换术接受了术前过敏检测。我们结合了一系列机构数据库来确定过敏咨询结果、围手术期抗生素方案以及最终随访时的无感染生存情况。
在 2576 例接受过敏检测的患者中,2493 例患者(97%)可使用头孢菌素。对于整个队列,28174 例关节置换术(94.9%)接受头孢唑林治疗,1521 例(5.1%)接受非头孢唑林抗生素治疗。接受头孢唑林治疗的关节置换术无感染生存情况显著高于接受非头孢唑林抗生素治疗的关节置换术,术后 1 个月、2 个月、1 年和 10 年无感染生存率分别高出 0.06%、0.56%、0.61%和 1.19%(p<0.001)。总体而言,校正美国麻醉医师学会(ASA)分级、关节置换术(TKA 或 THA)和体质量指数(BMI)后,接受头孢唑林治疗的患者发生 PJI 的风险降低 32%(p<0.001)。在 1 年和 10 年时,使用头孢唑林预防 1 例 PJI 需要治疗的患者数分别为 164 例和 84 例。因此,在 100 万例 TKA 和 THA 患者中,每年可预防 6098 例 PJI,10 年可预防 11905 例 PJI。
围手术期 TKA 和 THA 预防中使用非头孢唑林抗生素时,PJI 发生率显著升高,这突出了术前抗生素过敏检测增加头孢唑林使用率的积极影响。鉴于青霉素过敏阳性率较低,以及抗生素选择这一可改变的风险因素,我们建议对所有有青霉素和头孢菌素过敏史的患者进行围手术期检测和用药许可。
2019;101-B(6 Supple B):9-15.